Pyelonephritis - Pipeline Insight, 2025

This “Pyelonephritis- Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Pyelonephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pyelonephritis: Understanding

Pyelonephritis: Overview

Pyelonephritis is a type of urinary tract infection (UTI) that affects one or both kidneys. It is typically caused by bacteria that travel from the bladder up to the kidneys. This condition can be acute, meaning it occurs suddenly, or chronic, indicating long-term kidney infection or repeated episodes of acute pyelonephritis. If left untreated, pyelonephritis can lead to serious complications, including kidney damage, sepsis, and chronic kidney disease. The signs and symptoms of pyelonephritis often include fever, chills, flank pain (pain in the sides and back), nausea, vomiting, and frequent, painful urination. Patients may also experience symptoms typical of lower UTIs, such as urgency to urinate and cloudy or foul-smelling urine. In severe cases, there may be blood in the urine (hematuria). It's crucial for individuals experiencing these symptoms to seek medical attention promptly, as the infection can spread quickly to the bloodstream, leading to sepsis.

The primary cause of pyelonephritis is bacterial infection, most commonly by Escherichia coli (E. coli), which is normally found in the intestines. Other bacteria, such as Klebsiella, Proteus, and Enterobacter species, can also cause the infection. Risk factors include a history of UTIs, structural abnormalities in the urinary tract, urinary catheter use, and conditions that impair the immune system, such as diabetes. Women are more prone to pyelonephritis due to their shorter urethra, which facilitates the ascent of bacteria to the bladder and kidneys. Pathophysiologically, pyelonephritis involves the bacteria ascending from the lower urinary tract to the kidneys, triggering an inflammatory response. The infection can cause the renal parenchyma (the functional tissue of the kidney) to become inflamed, which can lead to abscess formation and scarring. Chronic pyelonephritis often results from repeated infections or ongoing obstruction in the urinary tract, leading to progressive kidney damage and loss of renal function over time. Diagnosis of pyelonephritis is based on clinical presentation, laboratory tests, and imaging studies. Urinalysis typically reveals the presence of white blood cells, bacteria, and sometimes red blood cells. Urine culture is performed to identify the causative organism and determine its antibiotic sensitivity. Blood tests may show elevated white blood cell counts and markers of inflammation. Imaging studies, such as ultrasound or CT scans, can be useful to assess the kidneys for abscesses, stones, or structural abnormalities. Treatment involves prompt initiation of antibiotics, with the choice of medication guided by the severity of the infection and the results of the urine culture. In severe cases, hospitalization and intravenous antibiotics may be required. Supportive care, including pain management and hydration, is also important. Chronic or recurrent pyelonephritis may necessitate further investigation and management of underlying conditions to prevent future infections.

”Pyelonephritis- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyelonephritis pipeline landscape is provided which includes the disease overview and Pyelonephritis treatment guidelines. The assessment part of the report embraces, in depth Pyelonephritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyelonephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pyelonephritis R&D. The therapies under development are focused on novel approaches to treat/improve Pyelonephritis.

Pyelonephritis Emerging Drugs Chapters

This segment of the Pyelonephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pyelonephritis Emerging Drugs

WCK 4282: Wockhardt

WCK 4282 is an investigational drug, which is designed to fill the critical therapeutic void by offering a significantly superior ESBL coverage as compared to piperacillin/tazobactam and cefoperazone/sulbactam along with excellent safety profile. It is a globally patented and pharmacodynamically optimized high dose combination of clinically well-established, cefepime and tazobactam. WCK 4282 had been designated as qualified infectious disease product (QIDP) by the US FDA. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with acute pyelonephritis.

Finafloxacin: MerLion Pharmaceuticals GmbH

Finafloxacin is a novel C-8-cyano 5th generation fluoroquinolone antibiotic with best-in-class features, developed by MerLion Pharmaceuticals GmbH. Finafloxacin combines well-known, significant efficacy and resistance-breaking capabilities with an outstanding safety profile. In clinical and pre-clinical settings, the compound has shown broad utility in treating different severe infections (including those caused by resistant Gram-negative pathogens) and a substantially improved therapeutic profile in comparison to existing gold standard therapies.The superior antibacterial profile of finafloxacin is due to a unique mode of action, being equally active at physiological pH conditions and in acidic environments, which occur at most bacterial infection sites. Most other antibiotics, including other fluoroquinolones, show reduced activity and subsequently reduced efficacy under acidic conditions. The drug is currently being evaluated under Phase II clinical trial for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis.

Pyelonephritis: Therapeutic Assessment

This segment of the report provides insights about the different Pyelonephritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pyelonephritis

There are approx. 8+ key companies which are developing the therapies for Pyelonephritis. The companies which have their Pyelonephritis drug candidates in the most advanced stage, i.e. Phase III include, Wockhardt.

Phases

The report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pyelonephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pyelonephritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pyelonephritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pyelonephritis drugs.

Pyelonephritis Report Insights

• Pyelonephritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pyelonephritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pyelonephritis drugs?
• How many Pyelonephritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pyelonephritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pyelonephritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pyelonephritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Wockhardt
• MerLion Pharmaceuticals GmbH
• Spero Therapeutics
• Pfizer

Key Products

• WCK 4282
• Finafloxacin
• Tebipenem HBr
• PF-07612577

This product will be delivered within 2 business days.